Search Press releases Keywords From To 23 May 2022 UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022 Read More 20 May 2022 Disposal of own shares Read More 18 May 2022 Transparency notification Wellington Read More 13 May 2022 Disposal of own shares Read More 13 May 2022 Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab Read More 10 May 2022 UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis Read More Pagination First page Previous page Previous … Page 17 Page 18 Page 19 Page 20 Current page 21 Page 22 Page 23 Page 24 Page 25 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
